Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|May 1, 2010
Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligandsJens-Uwe Peters, Torsten Hoffmann, Patrick Schnider, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonistsBernd Büttelmann, Jens-Uwe Peters, Simona Ceccarelli, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2010
Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonistsHassen Ratni, Theresa M Ballard, Caterina Bissantz, et al.
Science (New York, N.Y.)|September 18, 2012
Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autismStéphane J Baudouin, Julien Gaudias, Stefan Gerharz, et al.
EMBO Reports|May 30, 2002
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytesPhilipp J Kahle, Manuela Neumann, Laurence Ozmen, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2005
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activityRichard H P Porter, Georg Jaeschke, Will Spooren, et al.
Bioorganic & Medicinal Chemistry Letters|January 2, 2007
Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonistsGeorg Jaeschke, Richard Porter, Bernd Büttelmann, et al.
The Journal of Clinical Investigation|November 20, 2002
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathiesManuela Neumann, Philipp J Kahle, Benoit I Giasson, et al.
Plos One|August 15, 2015
Comprehensive Analysis of the 16p11.2 Deletion and Null Cntnap2 Mouse Models of Autism Spectrum DisorderDaniela Brunner, Patricia Kabitzke, Dansha He, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2011
CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitorLothar Lindemann, Georg Jaeschke, Aubin Michalon, et al.
Pageof 6